The civic record
Read. Follow. Verify.Oregon Expands Drug Manufacturer Annual Reporting to Include Patient Assistance Programs Starting in 2028
Last action · March 6, 2026: In committee upon adjournment.
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
What This Bill Proposed
Oregon Senate Bill 1528 expands annual reporting requirements for prescription drug manufacturers to include all s offered or funded by the manufacturer that provided consumer assistance in the state during the previous calendar year, becoming operative on January 1, 2028.
Drug manufacturers selling prescription drugs in the state must disclose detailed consumer assistance data, including participant counts, total cost-reduction values, and eligibility criteria, subjecting non-compliant manufacturers to civil penalties.
- Oregon's existing prescription drug price transparency laws require manufacturers to report certain price increases and drug development costs to the Department of Consumer and Business Services. context
- The Legislative Assembly utilizes annual reports compiled by the department to consider legislative measures aimed at containing prescription drug costs. context
Who It Would Have Affected
Groups the bill's text would have affected, as described in the record. Being affected is not a position for or against it.
Prescription drug manufacturers
Prescription drug manufacturers must compile and submit annual reports detailing patient assistance programs and pricing data to the Department of Consumer and Business Services and face potential civil penalties for non-compliance.
Consumers residing in this state
Consumers participate in patient assistance programs and have access to an online or telephone notification process to report prescription drug price increases to the department.
Department of Consumer and Business Services
The department is responsible for receiving reports, verifying data, posting information to its website, sharing data with the Prescription Drug Affordability Board, and reporting annually to the Legislative Assembly.
Key Facts
You don't have to trust us. Each fact below is taken straight from the official document - click any one to see the exact passage, highlighted in the original.
Frequently Asked Questions
What new information must drug manufacturers report under Senate Bill 1528?
What happens if a manufacturer fails to submit the required reports or provides inaccurate data?
What else do you want to know?
News Coverage
Follow the record
Votes, people, money & the original sourceWhere This Stands
This bill did not become law - Died at adjournment · passed the Senate · in House committee.
Procedural history
11 actions- Mar 6, 2026HouseIn committee upon adjournment.
- Mar 2, 2026HousePublic Hearing held.
- Feb 24, 2026HouseReferred to Rules.
- Feb 24, 2026HouseFirst reading. Referred to Speaker's desk.
- Feb 24, 2026SenateThird reading. Carried by Patterson. Passed.
- Feb 23, 2026SenateSecond reading.
Show 5 earlier actions
- Feb 20, 2026SenateRecommendation: Do pass with amendments. (Printed A-Eng.)
- Feb 16, 2026SenateWork Session held.
- Feb 11, 2026SenatePublic Hearing held.
- Feb 2, 2026SenateReferred to Health Care.
- Feb 2, 2026SenateIntroduction and first reading. Referred to President's desk.
Version history
Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.
View official text →Lobbying Activity
No state lobbying filings in our records match this bill. Federal lobbying reports (LDA) cover Congress, so they are not listed on state bills.
Full breakdown
Who this bill affects and the strongest case for and against it, written only from the bill’s own text.
Discoveries
Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.
Expansion of Annual Drug Reporting
Senate Bill 1528 broadens existing manufacturer price reporting mandates to encompass direct patient assistance programs such as copay cards and coupons.
Connected Entities
Sources
olis.oregonlegislature.gov
Analysis Score
0–100- Significance20Lowered because this bill did not pass (its text scored 65)
- Controversy40Intensity of disagreement among stakeholders
- Entertainment5Compellingness for a non-policy-wonk reader
- Buzz35Current news / social attention level
Publisher tools
